Literature DB >> 19721444

Golimumab.

Dimitrios A Pappas, Joan M Bathon, Delphine Hanicq, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19721444     DOI： 10.1038/nrd2982

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  14 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

Authors:  Désirée van der Heijde; Lars Klareskog; Vicente Rodriguez-Valverde; Catalin Codreanu; Horatiu Bolosiu; Jose Melo-Gomes; Jesus Tornero-Molina; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad
Journal:  Arthritis Rheum       Date:  2006-04

3.  Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Authors:  Honghui Zhou; Haishan Jang; Roy M Fleischmann; Esther Bouman-Thio; Zhenhua Xu; Joseph C Marini; Charles Pendley; Qun Jiao; Gopi Shankar; Stanley J Marciniak; Stanley B Cohen; Mahboob U Rahman; Daniel Baker; Mary Ann Mascelli; Hugh M Davis; Daniel E Everitt
Journal:  J Clin Pharmacol       Date:  2007-03       Impact factor: 3.126

4.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

5.  E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.

Authors:  Sudha Visvanathan; Carrie Wagner; Jeannie Rojas; Jonathan Kay; Bhaskar Dasgupta; Eric L Matteson; Michael Mack; Daniel G Baker; Mahboob U Rahman
Journal:  J Rheumatol       Date:  2009-06-01       Impact factor: 4.666

6.  Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

Authors:  Robert D Inman; John C Davis; Désirée van der Heijde; Laura Diekman; Joachim Sieper; Sung Il Kim; Michael Mack; John Han; Sudha Visvanathan; Zhenhua Xu; Benjamin Hsu; Anna Beutler; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2008-11

Review 7.  Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.

Authors:  Richard O Williams; Ewa Paleolog; Marc Feldmann
Journal:  Curr Opin Pharmacol       Date:  2007-07-12       Impact factor: 5.547

8.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Authors:  Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler
Journal:  Arthritis Rheum       Date:  2009-04

9.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  Edward Keystone; Désireé van der Heijde; David Mason; Robert Landewé; Ronald Van Vollenhoven; Bernard Combe; Paul Emery; Vibeke Strand; Philip Mease; Chintu Desai; Karel Pavelka
Journal:  Arthritis Rheum       Date:  2008-11

10.  Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Authors:  E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman
Journal:  Ann Rheum Dis       Date:  2008-12-09       Impact factor: 19.103
View more
  8 in total

1.  Fresh from the biologic pipeline-2009.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2010-04       Impact factor: 54.908

2.  Antibody fragments: hope and hype.

Authors:  Aaron L Nelson
Journal:  MAbs       Date:  2010-01-27       Impact factor: 5.857

3.  A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis.

Authors:  Xiao-Xiang Chen; Qing Dai; An-Bin Huang; Hua-Xiang Wu; Dong-Bao Zhao; Xing-Fu Li; Shao-Xian Hu; Nan-Ping Yang; Yi Tao; Jian-Hua Xu; Lin-Di Jiang; Chun-De Bao
Journal:  Clin Rheumatol       Date:  2012-10-04       Impact factor: 2.980

Review 4.  Golimumab and malignancies: true or false association?

Authors:  Ines Zidi; Aicha Bouaziz; Wissem Mnif; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

5.  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

Authors:  Jack T Stapleton; Nancy Wagner; Rebecca Tuetken; Abbie R Bellamy; Heather Hill; Sonnie Kim; Patricia L Winokur
Journal:  Vaccine       Date:  2020-04-12       Impact factor: 3.641

Review 6.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

Review 7.  Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.

Authors:  Paulo César Martins Urbano; Vanete Thomaz Soccol; Valderilio Feijó Azevedo
Journal:  Biologics       Date:  2014-07-31

Review 8.  Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.

Authors:  Zhiqiang An
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.